InventisBio Reports Results from the P-II Trial of D-2570 to Treat Moderate to Severe Plaque Psoriasis
Shots:
- InventisBio has reported the results from P-II study assessing the safety & efficacy of D-2570’s (oral selective TYK2 kinase inhibitor) three dose levels vs PBO to treat patients (n=161) with moderate to severe plaque psoriasis
- Study depicted PASI 75 in ≥85% vs 12.5% across all the dose levels, with PASI 100 (complete skin clearance) in 50% vs 2.5%, PASI 90 in 77.5% vs 5.0% & sPGA 0/1 in 87.5% vs 20% across high dose level at wk.12
- D-2570 was well-tolerated, with mostly mild to moderate AEs and no new safety signals; safety aligned with other TYK2 inhibitors. Full data will be highlighted at future conferences
Ref: PR Newswire | Image: InventisBio
Related News:- Minghui Pharmaceutical Reports Topline Data from P-III Study of Tofacitinib Etocomil (MH004) Ointment for Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
